Plain language summary of the FLAURA2 study: Impact of first-line osimertinib plus chemotherapy on brain health in patients with EGFR-mutated advanced non-small cell lung cancer

This Plain Language Summary of Publication article (PLSP) from Future Oncology, examined the effects of adding chemotherapy to osimertinib as a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), a type of lung cancer that often spreads to the brain. The study included patients with stable or treated brain metastases and found that combining chemotherapy with osimertinib helped delay tumor progression and extend survival compared to osimertinib alone.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.

• Advanced
• Central nervous system metastases
• EGFR gene mutation
• FLAURA2
• lay summary
• non-small cell lung cancer
• osimertinib
• plain language summary